References
1. Drugs@FDA: FDA-Approved Drugs.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=103705.
Accessed 22 Jul, 2020.
2. Yi Y, Lagniton PN, Ye S, Li E, Xu R-H. COVID-19: what has been
learned and to be learned about the novel coronavirus disease.International journal of biological sciences. 2020;16(10):1753.
3. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part
II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention,
and treatment. J Am Acad Dermatol. 2013;69(2):187 e181-116; quiz
203-184.
4. Ng QX, De Deyn M, Venkatanarayanan N, Ho CYX, Yeo WS. A meta-analysis
of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal
necrolysis. Journal of inflammation research. 2018;11:135-142.
5. Cour M, Ovize M, Argaud L. Cyclosporine A: a valid candidate to treat
COVID-19 patients with acute respiratory failure? Crit Care.2020;24(1):276.
6. Poulsen NN, von Brunn A, Hornum M, Blomberg Jensen M. Cyclosporine
and COVID-19: Risk or favorable? Am J Transplant. 2020.
7. Lagziel T, Quiroga L, Ramos M, Hultman CS, Asif M. Two False Negative
Test Results in a Symptomatic Patient with a Confirmed Case of Severe
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Suspected
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN).Cureus. 2020;12(5):e8198.
8. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID-19 and coagulation:
bleeding and thrombotic manifestations of SARS-CoV-2 infection.Blood. 2020;136(4):489-500.